Onconetix (NASDAQ:ONCO) Posts Quarterly Earnings Results, Beats Estimates By $44,973.99 EPS

Onconetix (NASDAQ:ONCO – Get Free Report) posted its quarterly earnings data on Monday. The company reported ($76.01) EPS for the quarter, beating the consensus estimate of ($45,050.00) by $44,973.99, FiscalAI reports. The business had revenue of $0.10 million during the quarter, compared to analyst estimates of $0.10 million. Onconetix had a negative net margin of 1,575.89% and a negative return on equity of 91.95%.

Onconetix Price Performance

ONCO opened at $3.00 on Wednesday. Onconetix has a 12 month low of $2.76 and a 12 month high of $1,610.00. The business has a fifty day moving average price of $5.99 and a 200 day moving average price of $102.80.

Wall Street Analyst Weigh In

Several equities research analysts recently weighed in on ONCO shares. Weiss Ratings raised shares of Onconetix from a “sell (e)” rating to a “sell (e+)” rating in a research note on Thursday, October 29th. Wall Street Zen upgraded shares of Onconetix from a “sell” rating to a “hold” rating in a report on Saturday, August 15th. One investment analyst has rated the stock with a Sell rating. Based on data from MarketBeat.com, the company has a consensus rating of “Sell”.

Get Our Latest Research Report on Onconetix

About Onconetix

(Get Free Report)

Onconetix, Inc. is a biotechnology company focused on cancer-related diagnostics and therapeutics, with an emphasis on prostate health. Its portfolio includes Proclarix, a blood-based diagnostic test developed to help assess prostate cancer risk. Proclarix was developed by Swiss company Proteomedix, which Onconetix acquired in 2023. The test has received a CE mark for use in Europe; its availability and regulatory status may differ in other markets. Onconetix was formerly known as Blue Water Biotech before adopting its current name in 2024.

Featured Stories

Earnings History for Onconetix (NASDAQ:ONCO)

Receive News & Ratings for Onconetix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Onconetix and related companies with MarketBeat.com's FREE daily email newsletter.